Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

• Published in: The New England journal of medicine Vol. 390; no. 23; pp. 2143 - 2155
• Main Authors: Melani, Christopher, Lakhotia, Rahul, Pittaluga, Stefania, Phelan, James D., Huang, Da Wei, Wright, George, Simard, Jillian, Muppidi, Jagan, Thomas, Craig J., Ceribelli, Michele, Tosto, Frances A., Yang, Yandan, Xu, Weihong, Davies-Hill, Theresa, Pack, Svetlana D., Peer, Cody J., Arisa, Oluwatobi, Mena, Esther, Lindenberg, Liza, Bergvall, Ethan, Portell, Craig A., Farah, Rafic J., Lee, Seung Tae, Pradhan, Amynah, Morrison, Candis, Tadese, Atekelt, Juanitez, Anna Marie, Lu, Crystal, Jacob, Allison, Simmons, Heidi, Figg, William D., Steinberg, Seth M., Jaffe, Elaine S., Roschewski, Mark, Staudt, Louis M., Wilson, Wyndham H.
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 20.06.2024
• Subjects: Adenine - administration & dosage; Adenine - adverse effects; Adenine - analogs & derivatives; Adenine - therapeutic use; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bcl-2 protein; Bcl-6 protein; Biopsy; Bridged Bicyclo Compounds, Heterocyclic - administration & dosage; Bridged Bicyclo Compounds, Heterocyclic - adverse effects; Bridged Bicyclo Compounds, Heterocyclic - therapeutic use; Disease prevention; Drug development; Drug dosages; Female; Hematology; Hemorrhage; Humans; Kinases; Lenalidomide - administration & dosage; Lenalidomide - adverse effects; Lenalidomide - therapeutic use; Leukemia; Lymphocytes B; Lymphoma; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - mortality; Male; Medical prognosis; Middle Aged; Molecular Targeted Therapy; Myc protein; Neutropenia; Oncology; Piperidines - administration & dosage; Piperidines - adverse effects; Piperidines - therapeutic use; Prednisone; Prednisone - administration & dosage; Prednisone - adverse effects; Prednisone - therapeutic use; Progression-Free Survival; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyrazoles - therapeutic use; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Recurrence; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Sulfonamides - therapeutic use; Thrombocytopenia; Tomography; Treatments in Oncology
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2401532

In a phase 1b–2 study, a five-agent treatment aimed at tumor survival pathways in relapsed and refractory diffuse large B-cell lymphoma was associated with a complete response in 38% of the patients.